Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Reborn interim report

<< Previous

Bullboard Posts

Next >>

Post by Golddetectoron Dec 30, 2021 9:20am

245 Views

Post# 34270309

Reborn interim report

I was hoping to see this today. It shows it is coming end of the on December presentation. It looks like we will need to wait for next week. I think they will announce it with the end of enrolment for reborn phase II trial. Mc at 50millions is a jock for phase II major pain drug. It is mostly due to the stupid timing of financing by Guy. Anyway let's see how the QIXLEEF performs against opioid. That will be a kill imo it is a direct comparison no room for confusion. Gl longs

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale